 Cytovia Therapeutics Inc and Cellectis SA NASDAQ: CLLS have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells iPSC Natural Killer NK and Chimeric Antigen Receptor CAR-NK cells. Cellectis will receive up to 760 million in milestone payments from Cytovia for the first five TALEN gene-edited iPSC-derived NK products. 